Unveiling Ga(III) phthalocyanine—a different photosensitizer in neuroblastoma cellular model

Phthalocyanines (Pc) and their metallated derivatives are strongly considered for photodynamic therapy (PDT) possessing unique properties as possible new photosensitizers (PS). We have used toxicological assessments, real‐time monitoring of cellular impedance, and imagistic measurements for assessin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2019-02, Vol.23 (2), p.1086-1094
Main Authors: Constantin, Carolina, Lupu, Andreea‐Roxana, Fertig, Tudor Emanuel, Gherghiceanu, Mihaela, Pop, Sevinci, Ion, Rodica‐Mariana, Neagu, Monica
Format: Article
Language:English
Subjects:
Cell Line, Tumor
Cell Proliferation - radiation effects
Cell Survival - radiation effects
Confocal microscopy
Gallium Radioisotopes - pharmacology
gallium(III)
Humans
Indoles - pharmacology
Microscopy
Neuroblastoma
Neuroblastoma - radiotherapy
Neuroblastoma cells
Original
Photochemotherapy - methods
Photodynamic therapy
photosensitizer
Photosensitizing Agents - pharmacology
proliferation
Toxicity
Toxicology
tumour
viability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phthalocyanines (Pc) and their metallated derivatives are strongly considered for photodynamic therapy (PDT) possessing unique properties as possible new photosensitizers (PS). We have used toxicological assessments, real‐time monitoring of cellular impedance, and imagistic measurements for assessing the in vitro dark toxicity and PDT efficacy of Ga(III)‐Pc in SHSy5Y neuroblastoma cells. We have established the non‐toxic concentration range of Ga(III)‐Pc, a compound which shows a high intracellular accumulation, with perinuclear distribution in confocal microscopy. By choosing Ga(III)Pc non‐toxic dose, we performed in vitro experimental PDT hampering cellular proliferation. Our proposed Ga(III)‐Pc could complete a future PS panel for neuroblastoma alternate therapy.
ISSN:1582-1838
1582-4934
DOI:10.1111/jcmm.14009